1)Kubo K, Kimura N, Matsuda S, et al. Vonoprazan-associated gastric mucosal redness:A report of four cases. Intern Med 59:507-511, 2020
2)Kubo K, Kimura N, Watanabe R, et al. Vonoprazan-associated gastric mucosal redness in non-Helicobacter pylori-infected and Helicobacter pylori-eradicated stomach. Case Rep Gastroenterol 15:751-758, 2021
3)Shinozaki S, Osawa H, Miura Y, et al. The effect of proton pump inhibitors and vonoprazan on the development of ‘gastric mucosal redness'. Biomed Rep 16:51, 2022
4)Miwa W, Hiratsuka T, Sato K, et al. Development of white globe appearance lesions in the noncancerous stomach after vonoprazan administration:a report of two cases with a literature review. Clin J Gastroenterol 14:48-58, 2021
5)Miyamoto S, Matsuno Y, Kato M, et al. Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan. Am J Gastroenterol 112:1899-1901, 2017
6)Stolte M, Bethke B, Rühl G, et al. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol 30:134-138, 1992
7)Kim GH. Proton pump inhibitor-related gastric mucosal changes. Gut Liver 15:646-652, 2021
8)Kushima R, Uemura N, Kinoshita Y, et al. 4-year interim analysis results of vision trial:a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Gastroenterology 162(Suppl):S1066-1067, 2022